Novo Nordisk Statistics
Total Valuation
Novo Nordisk has a market cap or net worth of $167.25 billion. The enterprise value is $183.70 billion.
| Market Cap | 167.25B |
| Enterprise Value | 183.70B |
Important Dates
The last earnings date was Wednesday, February 4, 2026, before market open.
| Earnings Date | Feb 4, 2026 |
| Ex-Dividend Date | Aug 18, 2025 |
Share Statistics
Novo Nordisk has 4.44 billion shares outstanding. The number of shares has decreased by -0.34% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.44B |
| Shares Change (YoY) | -0.34% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 28.45% |
| Float | 3.19B |
Valuation Ratios
The trailing PE ratio is 10.39 and the forward PE ratio is 11.35.
| PE Ratio | 10.39 |
| Forward PE | 11.35 |
| PS Ratio | 3.44 |
| Forward PS | 0.52 |
| PB Ratio | 5.48 |
| P/TBV Ratio | 16.62 |
| P/FCF Ratio | 17.94 |
| P/OCF Ratio | 8.93 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.62, with an EV/FCF ratio of 19.70.
| EV / Earnings | 11.41 |
| EV / Sales | 3.78 |
| EV / EBITDA | 7.62 |
| EV / EBIT | 8.31 |
| EV / FCF | 19.70 |
Financial Position
The company has a current ratio of 0.80, with a Debt / Equity ratio of 0.67.
| Current Ratio | 0.80 |
| Quick Ratio | 0.54 |
| Debt / Equity | 0.67 |
| Debt / EBITDA | 0.85 |
| Debt / FCF | 2.21 |
| Interest Coverage | 33.42 |
Financial Efficiency
Return on equity (ROE) is 60.70% and return on invested capital (ROIC) is 41.13%.
| Return on Equity (ROE) | 60.70% |
| Return on Assets (ROA) | 17.43% |
| Return on Invested Capital (ROIC) | 41.13% |
| Return on Capital Employed (ROCE) | 42.97% |
| Weighted Average Cost of Capital (WACC) | 6.03% |
| Revenue Per Employee | $699,061 |
| Profits Per Employee | $231,692 |
| Employee Count | 69,505 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 1.20 |
Taxes
In the past 12 months, Novo Nordisk has paid $4.42 billion in taxes.
| Income Tax | 4.42B |
| Effective Tax Rate | 21.53% |
Stock Price Statistics
The stock price has decreased by -58.18% in the last 52 weeks. The beta is 0.40, so Novo Nordisk's price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | -58.18% |
| 50-Day Moving Average | 52.29 |
| 200-Day Moving Average | 57.16 |
| Relative Strength Index (RSI) | 23.92 |
| Average Volume (20 Days) | 30,477,526 |
Short Selling Information
The latest short interest is 26.97 million, so 0.84% of the outstanding shares have been sold short.
| Short Interest | 26.97M |
| Short Previous Month | 28.16M |
| Short % of Shares Out | 0.84% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.04 |
Income Statement
In the last 12 months, Novo Nordisk had revenue of $48.59 billion and earned $16.10 billion in profits. Earnings per share was $3.62.
| Revenue | 48.59B |
| Gross Profit | 40.04B |
| Operating Income | 22.11B |
| Pretax Income | 20.52B |
| Net Income | 16.10B |
| EBITDA | 24.10B |
| EBIT | 22.11B |
| Earnings Per Share (EPS) | $3.62 |
Balance Sheet
The company has $4.24 billion in cash and $20.59 billion in debt, with a net cash position of -$16.35 billion or -$3.68 per share.
| Cash & Cash Equivalents | 4.24B |
| Total Debt | 20.59B |
| Net Cash | -16.35B |
| Net Cash Per Share | -$3.68 |
| Equity (Book Value) | 30.51B |
| Book Value Per Share | 6.86 |
| Working Capital | -6.79B |
Cash Flow
In the last 12 months, operating cash flow was $18.72 billion and capital expenditures -$9.45 billion, giving a free cash flow of $9.32 billion.
| Operating Cash Flow | 18.72B |
| Capital Expenditures | -9.45B |
| Free Cash Flow | 9.32B |
| FCF Per Share | $2.10 |
Margins
Gross margin is 82.41%, with operating and profit margins of 45.50% and 33.14%.
| Gross Margin | 82.41% |
| Operating Margin | 45.50% |
| Pretax Margin | 42.24% |
| Profit Margin | 33.14% |
| EBITDA Margin | 49.60% |
| EBIT Margin | 45.50% |
| FCF Margin | 19.19% |
Dividends & Yields
This stock pays an annual dividend of $1.23, which amounts to a dividend yield of 3.29%.
| Dividend Per Share | $1.23 |
| Dividend Yield | 3.29% |
| Dividend Growth (YoY) | 19.97% |
| Years of Dividend Growth | 6 |
| Payout Ratio | 33.99% |
| Buyback Yield | 0.34% |
| Shareholder Yield | 3.63% |
| Earnings Yield | 9.63% |
| FCF Yield | 5.57% |
Analyst Forecast
The average price target for Novo Nordisk is $54.25, which is 44.86% higher than the current price. The consensus rating is "Hold".
| Price Target | $54.25 |
| Price Target Difference | 44.86% |
| Analyst Consensus | Hold |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 3.73% |
| EPS Growth Forecast (5Y) | 3.45% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 20, 2023. It was a forward split with a ratio of 2:1.
| Last Split Date | Sep 20, 2023 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Novo Nordisk has an Altman Z-Score of 5.15 and a Piotroski F-Score of 5.
| Altman Z-Score | 5.15 |
| Piotroski F-Score | 5 |